Research Reports | Market Assessment
May 2015

Acute Heart Failure – How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market? | Decision Base | US/EU5 | 2015

How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market?

Acute heart failure (AHF) is one of the leading causes of hospitalization in the developed world, representing a significant healthcare burden. Treatment of AHF relies on different lines of therapy to relieve symptoms and to encourage sufficient hemodynamic stabilization. Long-term patient prognosis remains bleak: both mortality and hospital readmission rates are very high. The high attrition rate of drugs in development for AHF has resulted in a very genericized market in which no new therapies have launched since 2002. However, the AHF therapies in development boast promising new mechanisms of action and have the potential to fill the gaps in efficacy and safety left by current agents.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports